Skip to main content
. 2015 Oct 12;6(35):38270–38282. doi: 10.18632/oncotarget.5681

Table 5. Down-regulated mir-15a predicted poor survival in newly diagnosed MM patients receiving both thalidomide and bortezomib based therapy.

Subgroups Median PFS (months) P value Median OS (months) P value
Arm A 0.046 0.016
  Mir-15a low level (n = 8) 15.0 16.0
  Mir-15a high level (n = 38) 47.0 55.5
Arm B 0.003 0.002
  Mir-15a low level (n = 8) 13.5 16.0
  Mir-15a high level (n = 32) 29.0 Not reached